BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (Amex: DDD) announced today that it has received a second milestone payment under a previously disclosed License Agreement from Wyeth Consumer Healthcare, a division of Wyeth (NYSE: WYE). The cash payment under the SCOLR Pharma – Wyeth Consumer Healthcare agreement represents prepayment of a development milestone. SCOLR Pharma expects to report the payment as deferred research and development revenue for the quarter ending March 31, 2007.
